Sep 4 |
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
|
Sep 3 |
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
|
Aug 27 |
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
|
Aug 24 |
Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report
|
Aug 22 |
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
|
Aug 22 |
Biogen, Eisai new Alzheimer’s drug considered too costly in Britain
|
Aug 22 |
Eisai’s Leqembi deemed too costly for NHS
|
Aug 22 |
UK approves Leqembi, but reimbursement may not follow
|
Aug 22 |
Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain
|
Aug 22 |
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
|